Other PET Tracers and Prospects for the Future.
(18)F FDG-PET has proven its use as a technique in the field of melanoma, but there are valid concerns related to the specificity of (18)F FDG-PET findings and the degree of accuracy we can expect in the assessment of response to new treatment protocols. The main avenues currently being explored for future use in staging and management of melanoma with PET other than FDG include monoclonal antibodies against melanoma-associated antigens, α-MSH analogues, amino acids involved in melanin formation, nicotinamide-based compounds, heterodimeric glycoproteins such as integrins, reporter gene imaging, cell proliferation, and hypoxia tracers.